Year: 2022

Eledon to Incorporate the iBox Scoring System in Future Kidney Transplant Trials IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) — Critical Path Institute (C-Path) announced on December 20, 2022, that its Transplant Therapeutic Consortium (TTC) received a qualification opinion for the iBox Scoring System as a novel secondary efficacy endpoint for kidney transplant clinical trials through the European Medicines Agency’s (EMA) qualification of novel methodologies for drug development. This novel secondary endpoint supports the evaluation of new immunosuppressive therapy (IST) applications for the prevention of kidney transplant rejection and is the first EMA qualified endpoint for any transplant indication. The iBox Scoring System is a composite endpoint of kidney graft function that utilizes multiple clinical, histological...

SAN DIEGO, Dec. 21, 2022 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California. Singular Genomics’ management is scheduled to present on Thursday, January 12, 2023 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation on the News & Events section of the company’s investor relations website at https://investor.singulargenomics.com/news-events/event-calendar. About Singular Genomics Systems, Inc. Singular Genomics is a life science technology company that develops next-generation...

DENVER and VANCOUVER, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) —  SPOTLITE360 IOT SOLUTIONS, INC. (“SpotLite360” or the “Company”) (CSE: LITE) (OTC: SPLTF) (Frankfurt: 87A) announces that its board of directors has approved the settlement of an aggregate $78,375 of debt through the issuance of common shares of the Company (the “Debt Settlement”). Pursuant to the Debt Settlement, the Company issued 653,125 common shares of the Company (the “Shares”) at a deemed price of $0.12 per Share to a creditor of the Company. All securities issued are subject to a statutory hold period which will expire on the date that is four months and one day from the date of issuance. None of the securities issued in connection with Debt Settlement will be registered under the United States Securities Act of 1933, as amended...

Leveraging the Synchronoss Advanced Messaging Platform, NTT DOCOMO, KDDI, and SoftBank Deliver Cross-Operator Advanced Messaging Service Enabling Users and Brands to Communicate, Interact, and TransactBRIDGEWATER, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (NASDAQ: SNCR), a global leader and innovator in cloud, messaging and digital products and platforms, today announced a new milestone in Japan for its Synchronoss Advanced Messaging platform. In collaboration with mobile operators NTT DOCOMO, KDDI, and SoftBank, the Japanese consortium now supports 32.5 million subscribers of +Message, the cross-operator RCS service powered by Synchronoss Advanced Messaging. The current milestone represents a 62 percent increase in subscribers since Synchronoss noted the progress of...

San Antonio, Texas, Dec. 21, 2022 (GLOBE NEWSWIRE) — U.S. Global Investors, Inc. (NASDAQ: GROW) (the “Company”), a registered investment advisory firm with longstanding experience in global markets and specialized sectors, today announces that, following a rigorous and competitive review process, it has selected Grant Thornton LLP as its new independent registered public accounting firm. Grant Thornton LLP (GT) is the U.S. member of Grant Thornton International Ltd (GTIL). GT is a national firm with offices throughout the United States and GTIL is an international organization with member firms throughout the world. The change of the Company’s audit firm was approved by the Board of Directors (the “Board”). November Stock Buybacks In November 2022, the Company repurchased 24,795 of its shares at a net cost of around $73,600. This...

MOUNTAIN VIEW, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California. Management is scheduled to present on Thursday, January 12th, 2023 at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time. A live webcast of this event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://investors.neuropace.com.  About NeuroPace, Inc.Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE U.S. VANCOUVER, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) — Rover Metals Corp. (TSXV: ROVR) (OTCQB: ROVMF) (FSE:4XO) (“Rover” or the “Company”) is pleased to announce that further to its release of November 16, 2022, Rover has received approval from the Toronto Venture Exchange (TSXV) to close the second tranche of its $0.08 Unit Financing for gross proceeds of $202,000 (the “Second Closing”). The Company will issue 2,525,000 common shares and 2,525,000 warrants. Finders’ commissions are being paid in connection with the Second Closing in the amount of cash commissions of $3,500 and finders’ warrants of 43,750. The finder’s warrants will have an exercise price of $0.12 and a useful life of two and half (2 ½) years. The shares and warrants issued under...

Actemra is the first FDA-approved monoclonal antibody to treat COVID-19 Since the beginning of the pandemic, more than one million people hospitalised with COVID-19 have been treated with Actemra worldwide Actemra is approved for this use in more than 30 countries for the treatment of COVID-19Basel, 21 December 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra® (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalised adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Actemra is the first FDA-approved monoclonal antibody to treat COVID-19 and is recommended for use as a single 60-minute IV infusion....

CALGARY, Alberta, Dec. 21, 2022 (GLOBE NEWSWIRE) — LithiumBank Resources Corp. (TSX-V: LBNK) (OTCQX: LBNKF) (“LithiumBank” or the “Company”) announces the filing of the Boardwalk Lithium Brine Project Technical report entitled “Updated Indicated and Inferred Resource Estimates for LithiumBank Resources Corp.’s Boardwalk Lithium-Brine Project in West- Central Alberta, Canada” effectively dated December 20, 2022, originally announced November 7, 2022. The Technical Report includes NI 43-101 Mineral Resource Estimates of 393,000 tonnes of Indicated Lithium Carbonate Equivalent (LCE) at a grade of 71.6 mg/L and 5,808,000 tonnes of Inferred LCE at 68.0 mg/L lithium. The report is available on www.sedar.com. The Technical Report and Mineral Resource Estimates were prepared by the following Qualified Persons; Roy Eccles, P. Geol. of APEX...